Stacey L Martiniano
Overview
Explore the profile of Stacey L Martiniano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Metcalf A, Martiniano S, Sagel S, Zaretsky M, Zemanick E, Hoppe J
J Cyst Fibros
. 2024 Dec;
PMID: 39645477
As cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies including elexacaftor/tezacaftor/ivacaftor (ETI) have become widely used in eligible patients with cystic fibrosis (CF), the use of these medications in pregnant...
2.
Martiniano S, Caceres S, Poch K, Rysavy N, Lovell V, Armantrout E, et al.
J Cyst Fibros
. 2023 Sep;
23(1):50-57.
PMID: 37666709
Background: Nontuberculous mycobacteria (NTM) are an important cause of airway infections in people with cystic fibrosis (pwCF). Isolation of NTM from respiratory specimens of pwCF do not mandate treatment in...
3.
Martiniano S, Wu R, Farrell P, Ren C, Sontag M, Elbert A, et al.
J Pediatr
. 2023 Jul;
262:113595.
PMID: 37406853
Newborn screening for cystic fibrosis was fully implemented in the US by 2010, but delays in timeliness of evaluation for infants with positive newborn screening tests persist. Through evaluation of...
4.
Lenhart-Pendergrass P, Malcolm K, Wheeler E, Rysavy N, Poch K, Caceres S, et al.
Microbiol Spectr
. 2023 Jan;
11(1):e0327922.
PMID: 36651756
Nontuberculous mycobacteria (NTM), including Mycobacterium avium, are clinically important pathogens in cystic fibrosis (CF). The innate immune response to M. avium remains incompletely understood. We evaluated the role of complement...
5.
Nick J, Malcolm K, Hisert K, Wheeler E, Rysavy N, Poch K, et al.
Tuberculosis (Edinb)
. 2022 Nov;
138:102276.
PMID: 36417800
Nontuberculous mycobacteria (NTM) are opportunistic pathogens that affect a relatively small but significant portion of the people with cystic fibrosis (CF), and may cause increased morbidity and mortality in this...
6.
Martiniano S, Nick J, Daley C
Clin Chest Med
. 2022 Nov;
43(4):697-716.
PMID: 36344075
Nontuberculous mycobacteria (NTM) are important pathogens, with a longitudinal prevalence of up to 20% within the cystic fibrosis (CF) population. Diagnosis of NTM pulmonary disease in people with CF (pwCF)...
7.
Hoppe J, Zemanick E, Martiniano S
Am J Respir Crit Care Med
. 2022 Aug;
206(11):1308-1310.
PMID: 35947636
No abstract available.
8.
Sontag M, Miller J, McKasson S, Gaviglio A, Martiniano S, West R, et al.
Int J Neonatal Screen
. 2022 Jul;
8(3).
PMID: 35892468
Cystic fibrosis (CF) newborn screening (NBS) was universally adopted in 2009 in the United States. Variations in NBS practices between states may impact the timing of diagnosis and intervention. Quantitative...
9.
McColley S, Martiniano S, Ren C, Sontag M, Rychlik K, Balmert L, et al.
J Cyst Fibros
. 2022 Jul;
22(1):89-97.
PMID: 35871976
Objective: We evaluated whether implementation of cystic fibrosis (CF) newborn screening (NBS) leads to equitable timeliness of initial evaluation. We compared age at first event (AFE, age at sweat test,...
10.
Nick J, Dedrick R, Gray A, Vladar E, Smith B, Freeman K, et al.
Cell
. 2022 May;
185(11):1860-1874.e12.
PMID: 35568033
Two mycobacteriophages were administered intravenously to a male with treatment-refractory Mycobacterium abscessus pulmonary infection and severe cystic fibrosis lung disease. The phages were engineered to enhance their capacity to lyse...